Welcome to our dedicated page for Solid Biosciences news (Ticker: SLDB), a resource for investors and traders seeking the latest updates and insights on Solid Biosciences stock.
Solid Biosciences Inc. (Nasdaq: SLDB) is a Cambridge, MA-based biotechnology company focused on developing treatments and cures for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease. Solid Biosciences combines commercial acumen with top-tier science to advance promising therapies that address all aspects of DMD. The core of Solid's mission is to improve the daily lives of patients and target the roots of this debilitating condition.
The company's primary focus is on developing gene therapies and other treatments for neuromuscular and cardiac diseases. Their product pipeline includes:
- SGT-003: A next-generation gene therapy candidate for DMD, recently granted FDA clearance for an Investigational New Drug (IND) application. The therapy uses a proprietary capsid (AAV-SLB101) to deliver a microdystrophin transgene to promote muscle function and durability. The planned Phase 1/2 trial aims to evaluate the safety and tolerability of SGT-003 in pediatric patients.
- SGT-501: A treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT), a fatal childhood disease.
- AVB-401: For the treatment of BAG3-mediated dilated cardiomyopathy.
- AVB-202-TT: Aimed at treating Friedreich’s ataxia.
Solid Biosciences has made significant strides in obtaining regulatory milestones. Recently, SGT-003 was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by the FDA, enhancing its potential marketability and support for clinical development.
The company has also been involved in strategic collaborations and financing activities. Notably, Solid entered a licensing agreement with Armatus Bio for the use of its AAV-SLB101 capsid, securing a non-exclusive worldwide license and upfront and milestone payments. In January 2024, they raised $108.9 million from a private placement to support ongoing pipeline development and business activities.
Financially, Solid Biosciences reported a net loss of $96.0 million for 2023 but expects its cash reserves and recent financing to fund strategic priorities into 2026. As of December 31, 2023, the company had $123.6 million in cash, cash equivalents, and available-for-sale securities.
For more detailed information, visit www.solidbio.com.
Solid Biosciences Inc. (Nasdaq: SLDB) announced participation in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, scheduled for April 24, 2023, at 2:00 PM ET. The event will feature insights into the company's focus on developing genetic medicines for neuromuscular and cardiac diseases.
A live webcast will be accessible on the Company’s website, with a replay available afterward. Institutional investors interested in meetings during the conference can contact their Chardan representative. Solid Biosciences is known for programs like SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy, emphasizing a patient-centric approach to treatment.
Solid Biosciences Inc. (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023, at 8:00 AM ET. Additionally, he will join a gene therapy panel discussion later that same day at 11:45 AM ET. A live webcast of the presentation will be available on the company’s Investors section of their website, with a replay accessible post-event. The panel discussion will be exclusively available live to clients of Needham. Solid Biosciences is dedicated to developing genetic medicines targeting neuromuscular and cardiac diseases, with a focus on improving the daily lives of patients affected by these conditions.
Solid Biosciences (Nasdaq: SLDB) successfully completed the acquisition of AavantiBio, enhancing its focus on genetic medicines for cardiac and neuromuscular diseases. The company closed a $75 million private placement, positioning itself with approximately $214 million in cash, providing a runway into 2025. Solid is on track to submit an IND for SGT-003, a gene therapy for Duchenne muscular dystrophy, expected to commence dosing in late 2023. However, collaboration revenues decreased from $13.6 million in 2021 to $8.1 million in 2022, and the company's net loss widened to $86 million compared to $72.2 million in the previous year due to increased R&D investments.
Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will participate in a panel discussion titled “Innovative AAVs Targeting Diverse Tissues” during the BMO Biopharma Spotlight Series on March 28, 2023, at 9:00 AM ET. The live event is exclusive to BMO clients, with a replay available later on the Company’s website. Solid Biosciences is focused on developing genetic medicines for neuromuscular and cardiac diseases, with key programs including SGT-003 for Duchenne and AVB-401 for dilated cardiomyopathy. The Company aims to improve patients' lives through scientific and technological advancement.
Solid Biosciences Inc. (Nasdaq: SLDB) announced that its CEO Bo Cumbo will present at the Barclays Global Healthcare Conference on March 14, 2023, at 3:35 PM ET. A live webcast will be accessible on the Company's website, with a replay available post-event.
Institutional investors can contact their Barclays representative for potential meetings with management during the conference.
Solid Biosciences is committed to advancing genetic medicines for neuromuscular and cardiac diseases, including therapies for Duchenne and Friedreich’s Ataxia.
FAQ
What is the current stock price of Solid Biosciences (SLDB)?
What is the market cap of Solid Biosciences (SLDB)?
What is Solid Biosciences Inc. focused on?
What are the key products in Solid Biosciences' pipeline?
What recent regulatory milestones has Solid Biosciences achieved?
How is Solid Biosciences advancing its gene therapy programs?
What is the significance of the AAV-SLB101 capsid?
How does Solid Biosciences support its financial stability?
What is Duchenne muscular dystrophy (DMD)?
What is the planned Phase 1/2 trial for SGT-003?
What are the benefits of Orphan Drug Designation (ODD)?
How can I learn more about Solid Biosciences?
